Vistagen Therapeutics, Inc.
VTGN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001411685
No open-market purchases or sales by Vistagen Therapeutics, Inc. insiders were filed in the last 90 days; 48 institutions reported holding it in 13F filings for Q2 2026, worth $2.54M in total; no superinvestor holds it.
Q2 2024 vs. Q1 2024
How the institutions holding Vistagen Therapeutics, Inc. changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Q2 2024 | Change |
|---|---|---|---|
| Holders | 42 | 43 | +1 |
| Shares | 17.3M | 16.3M | −952.1K (−5.5%) |
| Value | $90.8M | $56.3M | −$34.5M (−38.0%) |
New holders (7)
Institutions that held Vistagen Therapeutics, Inc. at the end of Q2 2024 but not at the end of Q1 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Simplex Trading, LLC | 17,107 | $59.0K | 0.00% |
| Virtu Financial LLC | 15,488 | $54.0K | 0.00% |
| Squarepoint Ops LLC | 11,395 | $39.7K | 0.00% |
| FMR LLC | 4,146 | $14.4K | 0.00% |
| Royal Bank of Canada | 1,081 | $4.00K | 0.00% |
| Qube Research & Technologies Ltd | 492 | $1.71K | 0.00% |
| SJS Investment Consulting Inc. | 100 | $348 | 0.00% |
Sold out (6)
Institutions that held Vistagen Therapeutics, Inc. at the end of Q1 2024 and filed for Q2 2024 without it.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| ADAR1 Capital Management, LLC | 89,938 | $474.9K |
| Millennium Management LLC | 36,498 | $192.7K |
| Acadian Asset Management LLC | 32,291 | $169.0K |
| ExodusPoint Capital Management, LP | 18,443 | $97.0K |
| GPS Wealth Strategies Group, LLC | 8,441 | $44.6K |
| Wells Fargo & Company | 211 | $1.11K |